Biogen (BIIB) Cash & Equivalents (2009 - 2026)
Biogen (BIIB) reported Cash & Equivalents of $1.29 billion for Q2 2026, down 53.4% from $2.76 billion a year earlier and down 62.0% from the prior quarter.
Powered by 
Analysis
Biogen (BIIB) Cash & Equivalents (2009 - 2026) Analysis & Trends
At the end of FY2025, Biogen posted Cash & Equivalents of $3.01 billion, up 26.7% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of 17.7% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $2.38 billion in FY2024 (+126.2%), $1.05 billion in FY2023 (-69.3%), $3.42 billion in FY2022 (+51.2%) and $2.26 billion in FY2021 (+69.9%).
- The Q2 2026 figure ranks as the lowest quarterly Cash & Equivalents since Q1 2024.
- Year over year, Cash & Equivalents gained in six of the last eight quarters, with growth averaging 52.2%.
- The high point for year-over-year Cash & Equivalents in five years was Q1 2025 (growth of 141.8%); the low point was Q4 2023 (a decline of 69.3%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $3.38 billion (Q1 2026), $3.01 billion (Q4 2025) and $3.86 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,142.35 Bn | 1,110.94 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 635.52 Bn | 555.38 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 501.09 Bn | 474.20 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.35 Bn | 310.72 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 300.53 Bn | 264.52 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 263.02 Bn | 236.71 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 238.00 Bn | 193.40 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 194.35 Bn | 168.55 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 170.37 Bn | 117.02 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Biogen | 36.44 Bn | 23.10 Bn | 1.96 Bn | 1.29 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.29 Bn |
| Mar 31, 2026 | 3.38 Bn |
| Dec 31, 2025 | 3.01 Bn |
| Sep 30, 2025 | 3.86 Bn |
| Jun 30, 2025 | 2.76 Bn |
| Mar 31, 2025 | 2.60 Bn |
| Dec 31, 2024 | 2.38 Bn |
| Sep 30, 2024 | 1.70 Bn |
| Jun 30, 2024 | 1.91 Bn |
| Mar 31, 2024 | 1.07 Bn |
| Dec 31, 2023 | 1.05 Bn |
| Sep 30, 2023 | 2.29 Bn |
| Jun 30, 2023 | 2.62 Bn |
| Mar 31, 2023 | 2.90 Bn |
| Dec 31, 2022 | 3.42 Bn |
| Sep 30, 2022 | 3.68 Bn |
| Jun 30, 2022 | 2.65 Bn |
| Mar 31, 2022 | 1.75 Bn |
| Dec 31, 2021 | 2.26 Bn |
| Sep 30, 2021 | 1.54 Bn |
API Access
Biogen Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=BIIB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "BIIB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=BIIB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();